Tin tức & Cập nhật

3-year RUBY data support add-on dostarlimab as frontline Tx for endometrial cancer
3-year RUBY data support add-on dostarlimab as frontline Tx for endometrial cancer
17 Apr 2025
Does CKD reduce tirzepatide benefits on HFpEF patients with obesity?
Does CKD reduce tirzepatide benefits on HFpEF patients with obesity?
15 Apr 2025 bởiStephen Padilla

Long-term treatment with tirzepatide results in improved renal function in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, regardless of the absence or presence of chronic kidney disease (CKD), according to a post hoc analysis of the SUMMIT trial presented at ACC.25.

Does CKD reduce tirzepatide benefits on HFpEF patients with obesity?
15 Apr 2025